Adaptive plasicity during stress and depression and the role of glutamate-nitric oxide pathways

South African Psychiatry Review

Volumn 9, Issue 3, 2006, Pages 132-139

  Harvey, B H ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Depression; Glutamate; Neuroplasticity; Nitric oxide; PTSD; Stress

Indexed keywords

4 AMINOBUTYRIC ACID; AMINE OXIDASE (FLAVIN CONTAINING); ANTIDEPRESSANT AGENT; CYCLIC GMP; CYCLOSERINE; FLUOXETINE; GLUCOCORTICOID; GLUTAMIC ACID; IMIPRAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; KETOCONAZOLE; LITHIUM DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SILDENAFIL;

ADAPTATION; BRAIN ATROPHY; BRAIN DAMAGE; BRAIN FUNCTION; BRAIN RADIOGRAPHY; BRAIN REGION; CELL METABOLISM; COGNITION; CORRELATION ANALYSIS; DEPRESSION; DIAGNOSTIC ERROR; DRUG EFFICACY; DRUG TARGETING; EVIDENCE BASED MEDICINE; EXCITOTOXICITY; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HUMAN; MEMORY; MENTAL DISEASE; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT COMPLIANCE; PHENOMENOLOGY; POSTTRAUMATIC STRESS DISORDER; PREDICTION; PREVALENCE; RECURRENCE RISK; REVIEW; STRESS; SYNAPSE; THERAPY EFFECT; THERAPY RESISTANCE;

EID: 33751307186     PISSN: 18117805     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J. SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst Rev 2000;(2): CD001851.
2. Compton MT, Nemeroff CB. The treatment of bipolar depression. J Clin Psychiatry 2000; 61 suppl 9: 57-67.
3. Kocsis JH. Pharmacotherapy for chronic depression. J Clin Psychol 2003; 59: 885-892.
4. Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 2000; 48: 766-777.
5. D'Sa C, Duman RS. Antidepressants and neuroplasticity. Bipolar Disorders 2002; 4: 184-194.
6. Elzinga BM, Bremner JD. Are the neural substrates of memory the final common pathway in posttraumatic stress disorder (PTSD) ? J Affective Dis 2002; 70: 1-17.
7. Vermetten E, Vythilingam M, Southwick SM, Charney DS, Bremner JD. Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biol Psychiatry 2003; 54: 693-702.
8. McEwen BS, Stress and hippocampal plasticity. Ann Rev Neurosci 1999; 22: 105-122.
9. MacQueen GM, Campbell S, McEwen BS, MacDonald K, Amano S, Joffe RT, Nahmias C, Young LT. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci USA 2003, 100: 1387-1392.
10. Shelme Y, Sanghavi M, Mintun M, Gado M. Depression duration but not age predicts hippocampal volume loss in medical healthy women with recurrent major depression. J Neuroscience 1999; 19: 5034-5043.
11. Harvey BH. The neurobiology and pharmacology of depression: a comparative overview of the serotonin-selective antidepressants. S Afr Med J 1997; 87: 540-552.
12. Stein DJ, Zungu-Dirwayi N, van Der Linden GJ, Seedat S. Pharmacotherapy for posttraumatic stress disorder. Coch Datab Syst Rev 2000; 4: CD002795.
13. Gilbertson MW, Shenton ME, Ciszewski A, et al. Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma. Nature Neurosci 2002; 5: 1242-1247
14. Swaab DF, Bao AM, Lucassen PJ. The stress system in the human brain in depression and neurodegeneration. Age Res Rev 2005; [E-pub ahead of print].
15. Malberg JE, Schechter LE. Increasing hippocampal neurogenesis: a novel mechanisms for antidepressant drugs. Curr Pharm Des 2005; 11: 145-155.
16. McEwen BS. Protection and damage from acute and chronic stress: allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders. Annal NY Acad Sci 2004; 1032: 1-7.
17. Heuser I, Lammers CL. Stress and the brain. Neurobiol Aging, 2003; 24: S69-S76.
18. Shiah IS, Yatham LS. GABA function in mood disorders: An update and critical evidence. Life Sci 1998; 63: 1289-1303
19. Kendell SF, Krystal JH, Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin Ther Targets 2005; 9: 153-168.
20. Oosthuizen F, Wegener G, Harvey BH. Role of nitric oxide as inflammatory mediator in post-traumatic stress disorder (PTSD): Evidence from an animal model. Neuropsych Dis Treat 2005; 1: 109-124.
21. Chambers RA, Bremner JD, Moghaddam B, Southwick SM et al. Glutamate and post-traumatic stress disorder: Towards a psychobiology of dissociation. Semin Clin Neuropsychiatry 1999; 4: 274-281.
22. McEwen BS, Conrad CD, Kuroda Y, Frankfurt M et al. Prevention of stress-induced morphological and cognitive consequences. Eur Neuropsychopharmacol 1997; 7: 323-328.
23. McLeod TM, Lopez-Figueroa AL, Lopez-Figueroa MO. Nitric oxide, stress, and depression. Psychopharmacol Bull 2001; 35: 24-41.
24. Sapolsky RM, Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000; 57: 925-935.
25. Skolnick P. Antidepressants for the new millenium. Eur J Pharmacol 1999; 375: 31-40.
26. B receptor-mediated presynaptic inhibition of glutamatergic and GABA'ergic transmussion in the basolateral amygdala. Neuropharmacology 1999; 38: 1743-1753.
27. Dawson VL, Dawson TM. Physiological and toxicological actions of nitric oxide in the central nervous system. In Ignarro L and Murad F. Volume eds. Nitric oxide: biochemistry, molecular biology, and therapeutic implications. London: Academic Press 1995; 323-330.
28. Prast H, Philippu A. Nitric oxide as modulator of neuronal function. Prog Neurobiol 2001; 64: 51-68.
29. Harvey BH. Affective disorders and nitric oxide: A role in pathways to relapse and refractoriness. Human Psychopharmacology 1996; 11: 309-319.
30. Soderling SH, Beavo JA. Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions. Curr Opin Cell Biol 2000; 12: 174-9.
31. Vincent SR, Kimura H. Histochemical mapping of nitric oxide synthase in the rat brain. Neurosci 1992; 46: 755-784.
32. Krukoff M, Khalili P. Stress-induced activation of nitric oxide-producing neurons in the rat brain. J Comp Neurol 1997; 377: 509-519.
33. Eroglu L, Caglayan B. Anxiolytic and antidepressant properties of methylene blue in animal models. Pharmacol Res 1997; 36: 381-385.
34. Heiberg IL, Wegener G, Rosenberg R. Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats. Behav Brain Res 2002; 134: 479-484.
35. Padovan CM, Del Bel EA, Guimaraes FS. Behavioral effects in the elevated plus maze of an NMDA antagonist injected into the dorsal hippocampus: influence of restraint stress, Pharmacol Biochem Behav 2000; 67: 325-30.
36. Volke V, Wegener G, Bourin M et al. Antidepressant- and anxiolytic-like effects of selective neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole (TRIM) in mice. Behav Brain Res 2003a; 140: 141-147.
37. Volke V, Wegener G, Vasar E. Augmentation of the NO-cGMP cascade induces anxiogenic-like effect in mice. J Physiol Pharmacol 2003b; 54: 653-60.
38. Kurt M, Bilge SE, Aksoz E, Kukula O, Cehk S, Kesim Y. Effect of sildenafil on anxiety in the plus-maze test in mice. Pol J Pharmacology 2004; 56: 353-357.
39. Van Praag HM. Can stress cause depression? Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 891-907.
40. Leonard BE. Fundamentals of Psychopharmacology 3rd ed, John Wiley and Sons, Chichester UK, 2003.
41. Harvey BH, McEwen BS, Stein DJ. Neurobiology of antidepressant withdrawal: Implications for the longitudinal outcome of depression. Biol Psychiatry 2003a; 54: 1105-1117.
42. Basco MR, Rush AJ. Compliance of pharmacotherapy in mood disorder. Psychiatr Ann 1995; 25: 269-279.
43. Nierenberg AA. Long-term management of chronic depression. J Clin Psychiatry 2002; 62 S6: 17-21.
44. Judd LL, Alkiskal HS, Maser JD, Zeller PJ et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998; 50: 97-108.
45. Keller MB, Boland RJ. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry 1998, 44: 348-360.
46. Michelson D, Amsterdam J, Apter J, Fava M et al. Hormonal markers of stress response following interruption of selective serotonin reupake inhibitor treatment. Psychoneuroendocrinology 2000; 25: 169-177.
47. Harvey BH, Jonker LP, Brand L, Heenop M, Stein DJ. NMDA receptor involvement in imipramine withdrawal-associated effects on swim stress, GABA levels and NMDA receptor binding in rat hippocampus. Life Sci 2002; 71: 45-57.
48. Altamura C, Maes M, Dai J, Meltzer HY. Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur Neuropsychopharmacol 1995; 5 suppl: 71-75.
49. Mauri MC, Ferrara A, Boscati L, Bravin S et al. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 1998; 37: 124-129.
50. Boyer PA, Skolnick P, Fossum LH. Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNA's in mouse brain. J Mol Neuro Sci 1998; 10: 219-233.
51. 2A/C receptors. Met Brain Dis (in press).
52. Harkin AJ, Bruce KH, Craft B, Paul IA. Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 1. Acute treatments are active in the forced swim test. Eur J Pharmacol 1999; 372: 207-13.
53. Wegener G, Volke V, Harvey BH, Rosenberg R. Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res 2003' 959: 128-134.
54. Rogó Z, Skuza G, Maj J, Danysz W. Synergistic effects of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology 2002; 42: 1024-1030.
55. Harkin A, Connor TJ, Burns MP, Kelly JP. Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. Eur Neuropsychopharmacol 2004; 14: 274-81.
56. Harkin A, Connor TJ, Walsh M, St John N, Kelly JP. Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology 2003; 44: 616-23.
57. Schatzberg AF, Haddad P, Kaplan EM, Lejoyeux M et a]. Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. J Clin Psychiatry 1997; 58 S7: 23-27.
58. Zajecka J, Tracey KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 2002; 58: 291-297.
59. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996; 16: 356-362.
60. Vaidya VA, Rewilliger RMZ, Duman RS. Role of 5HT2A receptors in the stress-induced down-regulation of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci Lett 1999; 262: 1-4.
61. McEwen BS. Possible mechanisms for atrophy of the human hippocampus. Mol Psychiatry 1997; 2: 255-262.
62. Nowak G, Ordway GA, Paul LA. Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 1995; 675: 157-164.
63. Law AJ, Deakin JF. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 2001; 12: 2971-2974.
64. Berk M, Plein H, Ferreira D. Platelet glutamate receptor supersensitivity in major depressive disorder. Clin Neuropharmacol 2001; 24: 129-132.
65. Stryjer R, Strous RD, Shaked G, Bar F, Feldman B, Kotler M, Pola Rosenzrwaig S, Weizman A. Amantadine as augmentation therapy in the management of treatment resistant depression. Int Clin Psychopharmacol 2003; 18: 93-96.
66. Suzuki E, Yagi G, Nakaki T et al. Elevated plasma nitrate levels in depressive states. J Affect Disord 2001; 63: 221-224.
67. Xing G, Chavko M, Zhang LX, Yang S, Post RM, Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression. Schizophrenia Res 2002; 58: 21-30.
68. Yanik M, Vural H, Tutkun H, Zoroglu SS, Savas HA, Herken H, Kocyigit A, Keles H, Akyol O. The role of the arginine-nitric oxide pathway in the pathogenesis of bipolar affective disorder. Eur Arch Psychiatry Clin Neurosci 2004 254: 43-7.
69. Reif A, Strobel A, Jacob CP, Herterich S, Freitag CM, Topner T, Mossner R, Fritzen S, Schmitt A, Lesch KP. A NOS-III haplotype that includes functional polymorphisms is associated with bipolar disorder. Int J Neuropsychopharmacol 2005; 21:1-8
70. Harvey BH, Carstens ME, Taljaard JJF. Evidence that lithium induces a glutamatergic:nitric oxide - mediated response in rat brain. Neurochemical Research 1994; 19: 469-474.
71. Maruta S, Suzuki E, Yokoyama M, Sato T, Inada K, Watanabe S, Miyaoka H. Effects of intraperitoneally injected lithium, imipramine and diazepam on nitrate levels in rat amygdala. Psychiatry Clin Neurosci 2005; 59: 358-61.
72. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, APA, Washington, DC, USA, 1994.
73. Schelling G, Kilger E, Roozendaal B, de Quervain DJF et al. Stress doses of hydrocortisone, traumatic memories, and symptoms of posttraumatic stress disorder in patients after cardiac surgery: a randomized study. Biol Psychiatry 2004; 55: 627-633.
74. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 2003; 160:1554-65.
75. Rasmusson AM, Vythilingam M, Morgan CA 3rd. The neuroendocrinology of posttraumatic stress disorder: new directions. CNS Spectr 2003; 8: 651-657.
76. Yehuda R, Bierer LM, Schmeidler J, Aferiat DH, Breslau I, Dolan S. Low cortisol and risk for PTSD in adult offspring Holocaust survivors. Am J Psychiatry 2000; 157: 1252-1259.
77. Yehuda R, Harvey H. Relevance of neuroendocrine alterations in PTSD to cognitive impairments of trauma survivors, In: Read D, Lindsay S (eds.). Recollections of Trauma: Scientific Research and Clinical Practice. New York: Plenum Press 1997; 221-252.
78. De Kloet ER, Oitzl MS, Joels M. Stress and cognition: are corticosteroids good or bad guys? Trends Neurosci 1999; 22: 422-6.
79. Maes M, Mylle J, Delmeire L, Janca A. Pre- and post-disaster negative life events in relation to the incidence and severity of post-traumatic stress disorder. Psychiatry Res 2001; 105: 1-12.
80. Pitman RK, Shin LM, Rauch SL. Investigating the pathogenesis of post-traumatic stress disorder with neuroimaging. J Clin Psychiatry 2001; 62 suppl 17: 47-54.
81. Heresco-Levy U, Jivitt DC. The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes. Eur Neuropsychopharmacol 1998; 8:141-152.
82. Brown ES, Rush AJ, McEwen BS. Hippocampal remodeling and damage by corticosteroids: implications for mood disorders. Neuropsychopharmacology 1999; 21: 474-484.
83. Madrigal JLM, Moro MA, Lizasoani I et a]. Inducible nitric oxide synthase express on in brain cortex after acute restraint stress is regulated by nuclear factor kappaB-mediated mechanisms. Journal of Neurochemistry 2001; 76: 532-538.
84. De Oliviera RM, Aparecida Del Bel E, Mamede-Rosa ML, Padovan CM, Deakin JF, Guimaraes FS. Expression of neuronal nitric oxide synthase mRNA in stress-related brain areas after restraint in rats. Neuroscience Letters 2000; 289: 123-126.
85. 1A-2A receptor changes evoked by a time-dependent sensitization (TDS) stress model in rats. Brain Res 2003b; 983: 97-107.
86. Harvey BH, Naciti C, Brand L, Stein DJ. Serotonin and stress: Protective or malevolent actions in the biobehavioural response to repeated trauma. Annal NY Acad Sci 2004a; 1032: 267-272.
87. Harvey BH, Oosthuizen F, Brand, Wegener G, Stein DJ. Stress-restress evokes sustained iNOS activity and altered GABA levels and NMDA receptors in rat lippocampus. Psychopharmacology 2004b; 175: 494-502.
88. Campbell IK, Roberts LJ, Wicks IP. Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis. Immunol Cell Biol 2003; 81: 354-66.
89. Maes M, Lin AH, Delmeire L, Van Gastel A, et al. Elevated serum interleukin-6 an interleukin-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. Biol Psychiatry 1999; 45: 833-839.
90. Baker DG, Ekhator NN, Kasckow JW et al. Plasma and cerebrospinal fluid interleukin-6 concentrations in posttraumatic stress disorder. Neuroimmunomodulation 2001; 9: 209-217.
91. Harvey BH, Bothma T, Nel A, Wegener G, Stein DJ. Involvement of the NMDA receptor, NO-cyclic GMP and nuclear factor k-b in an animal model of repeated trauma. Human Psychopharmacol 2005b; 20: 367-73.
92. Yeh CB, Leckaman JF, Wan FJ, Shiah IS, Lu RB. Characteristics of acute stress symptoms and nitric oxide concentration in young rescue workers in Taiwan. Psychiatry Res 2002; 112: 59-68.
93. Heresco-Levy U, Kremer I, Javitt DC, Goichman R et al. Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol 2002; 5: 301-7
94. Kessler RC, McGonagle KC, Zhao S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Archives of General Psychiatry 1994; 51, 8-19.
95. Murray CJL, Lopez AD. Global Burden of Disease: A Comprehensive Assessment of Mortality and Morbidity from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020, Vol I. Harvard: World Health Organization. Harvard, World Health Organization, 1996.
96. Dupont R L, Rice DP, Miller LS, et al. Economic costs of anxiety disorders. Anxiety 1996; 2, 167-172.
97. Greenberg PE, Sisitsky T, Kessler RC, Finkelstein S, Berndt ER, Davidson JR T, et al. The economic burden of the anxiety disorders in the 1990s. J Clin Psychiatry 1999; 60, 427-435.
98. Tanno AP, Bianchi FJ, Costa Sampaio Moura MJ, Marcondes FK. Atrial supersensitivity to noradrenaline in stressed female rats. Life Sci 2002; 71: 2973-981.
99. Matsuoka N, Kodama H, Arakawa H, Yamaguchi I. N-Methyl-D-aspartate receptor blockade by dizocilpine prevents stress-induced sudden death in cardiomyopathic hamsters. Brain Res 2002 944: 200-4.
100. Stein DJ, Seedat S, Carey P, Harvey BH. Precursors, early detection, and prevention of anxiety disorders. In: M Maj, Lopez-Ibor JJ, Sartorius N, Sato M, Okasha A (eds), Early Detection and Management of Mental Disorders, John Wiley and Sons, Chichester, UK, 2005; pp 231-248.